A. Budzar

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

M. Dowsett, M. Piccart, J. Robertson, 2020, Clinical Cancer Research.

ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials

M. Ellis, A. Howell, J. Robertson, 2001 .

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

J. Cuzick, J. Forbes, J. Klijn, 2002, The Lancet.